Sera Prognostics, Inc., a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in asymptomatic singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preeclampsia, molecular time-to-birth, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.

NASDAQ:SERA

Sera Prognostics, Inc.

Last Close

7.86

25/09 14:32

Market Cap

168.25M

Beta: -

Volume Today

43.39K

Avg: 1.42M

PE Ratio

−6.67

PFCF: −8.92